small molecule

PLIAGLIS

LIDOCAINE; TETRACAINE

Loss of exclusivityJanuary 2031latest FDA-listed patent expiry

CompanyCrescita Therapeutics Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand name	PLIAGLIS
Active ingredient	LIDOCAINE; TETRACAINE
Strength	7%;7%
Dosage form	CREAM
Route	TOPICAL
Modality	Small molecule
FDA approval	June 2006
Marketing status	RX

Listed patents

Patent	Expires	Type
12558328	January 2031	use U-4421
10603293	January 2031	product
10751305	January 2031	product
10350180	January 2031	product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.